Collects data and samples from people with retroperitoneal sarcoma treated with surgery
Records information and tumor samples from adults with retroperitoneal sarcoma who have surgery.
Key facts
- Who runs it
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Where
- Boston, Columbus, Emory, Jacksonville, Los Angeles, and Tampa, United StatesSee the 6 sitesAlso in 10 other countries, 16 sites
- Trial code
- Registry title
- REtroperitoneal SArcoma Registry: an International Prospective Initiative
- Status
- Recruiting
- People taking part
- 2,000 people, planned
- Started
- 1 Sept 2016
- Expected to end
- 31 Dec 2030
- Type of study
- Observational
- Record updated
- 12 February 2019
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a first (primary) retroperitoneal sarcoma who are being operated on at a taking-part centre. It collects data and tissue samples to follow results.
- Age
- Older than 18 years at the time of first treatment
- Sex
- All
- Disease stage
- Primary retroperitoneal sarcoma, confirmed under the microscope by a sarcoma pathologist, with a contrast CT scan and/or MRI done before surgery
- Earlier treatment
- No earlier treatment is asked for; the tumour must be a first tumour, not a recurrence, and surgery is done at the taking-part centre
Main reasons for not taking part
- Under 18 years
- Tumour that has come back (recurrent tumour)
- Benign (non-cancerous) retroperitoneal tumours
- Serious psychiatric illness that prevents informed consent or follow-up
- Follow-up cannot be ensured
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- primary RPS operated on in the participating center
- age>18 years at the time of the first treatment (pediatric patients can not be included)
- histological confirmed diagnosis according to the WHO criteria done on biopsy or surgical specimen by dedicated sarcoma pathologist
- radiological examinations performed (contrast enhanced abdominal CT scan and/or MRI) prior to surgical resection
- signed informed consent form
- adequate compliance of the patients to the plan of follow-up
Who cannot take part
- serious psychiatric disease that precludes informed consent or limits compliance
- age<18 years
- recurrent tumor
- benign retroperitoneal tumors
- impossibility to ensure adequate follow-up
Where in United States
Also in 10 other countries, 16 sites
- Brigham and Women's Hospital / Dana-Farber Cancer InstituteBoston, United StatesContact: Chan Raut, MDTaking people
- The Ohio State UniversityColumbus, United StatesContact: Raphael Pollock, MDTaking people
- Winship Cancer InstituteEmory, United StatesContact: Kenneth Cardona, MDTaking people
- Mayo ClinicJacksonville, United StatesContact: Sanjay Bagaria, MDTaking people
- University of Southern California (USC)Los Angeles, United StatesContact: William Tseng, MDTaking people
- Moffitt Cancer CenterTampa, United StatesContact: John Mullinax, MDTaking people
About the trial
What the trial wants to find out
Surgery is currently the only potentially curative treatment modality for localized retroperitoneal sarcoma (RPS). Available studies regarding oncologic outcomes are mainly retrospective in nature, and RPS are recognized as a rare disease. Therefore, prospective analysis of high quality data is a top priority.
Read full original descriptionShow less
Primary Objectives of this study are:
* to prospectively collect standardized clinical data and radiological and pathological material from primary RPS patients treated with surgery at reference centers. * patient outcome will be evaluated in terms of overall survival (OS), disease-free survival (DFS), crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM).
Secondary Objectives:
* to estimate the efficacy and safety of surgical treatment, including extended surgical approach to primary RPS; * to prospectively evaluate the impact of multimodality therapy, including radiation therapy and chemotherapy; * to identify clinical, radiological and pathological characteristics that may influence the oncological outcome or may be used as predictors of LR/DM/OS. These may be important biomarkers of disease; * to utilize collected pathological material for research collaborations.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- REtroperitoneal SArcoma Registry (RESAR): Prospective Collection of Primary Retroperitoneal Sarcoma Patient's Data, Radiological and Pathological Material for the TransAtlantic Retroperitoneal Sarcoma Working Group
- Plain-language title
- Collects data and samples from people with retroperitoneal sarcoma treated with surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Pancreaticoduodenectomy and IVC resection in retroperitoneal sarcoma: Expanding the limits of feasible surgery.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2026
- Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.eLife, 2025
- Identification of NINJ1 as a novel prognostic predictor for retroperitoneal liposarcoma.Discover oncology, 2024
- Record updated
- 12 February 2019